Related Experiment Videos
Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma
Y Nakahara1, H Nagai, T Kinoshita
1First Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Abstract:
The PTEN/MMAC1 gene at 10q23.3, which has dual specific phosphatase activity, is a novel tumor suppressor gene candidate. Various kinds of tumors have mutations in this gene, including glioblastoma, endometrial carcinoma and prostate cancer. We examined 29 cases of primary non-Hodgkin's lymphoma (NHL) for mutations in the PTEN/MMAC1 gene. One case of diffuse large B cell lymphoma had an 11 bp deletion, but the remaining 28 cases showed no mutations in the genome. Two of these 28 cases showed missense mutations in the PTEN/MMAC1 transcripts, but no alterations in the genomic DNA. These mRNA missense variants are similar to PTEN/MMAC1 transcript aberrations which have been reported in patients with breast cancer. These findings suggest that alterations in the PTEN/MMAC1 gene play a role in the pathogenesis of NHL.
Insights
Alterations in the PTEN/MMAC1 gene may contribute to non-Hodgkin's lymphoma (NHL) development. While most NHL cases showed no genomic mutations, some exhibited transcript variations, suggesting a role in NHL pathogenesis.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- The PTEN/MMAC1 gene, a tumor suppressor, is frequently mutated in various cancers.
- PTEN/MMAC1 has dual-specific phosphatase activity and is located at 10q23.3.
- Mutations in PTEN/MMAC1 are implicated in glioblastoma, endometrial carcinoma, and prostate cancer.
Purpose of the Study:
- To investigate the role of PTEN/MMAC1 gene mutations in the pathogenesis of primary non-Hodgkin's lymphoma (NHL).
Main Methods:
- Genomic DNA and mRNA from 29 primary non-Hodgkin's lymphoma (NHL) cases were analyzed for PTEN/MMAC1 mutations.
- Mutation screening involved examining both the gene's genomic sequence and its transcripts.
Main Results:
- One case of diffuse large B cell lymphoma presented an 11 bp deletion in the PTEN/MMAC1 gene.
- The remaining 28 cases showed no genomic mutations.
- Two cases exhibited missense mutations in PTEN/MMAC1 transcripts without corresponding genomic alterations.
- These transcript variants resemble those found in breast cancer patients.
Conclusions:
- PTEN/MMAC1 gene alterations, particularly at the transcript level, may play a role in the development of non-Hodgkin's lymphoma (NHL).
- The findings suggest that PTEN/MMAC1 aberrations contribute to NHL pathogenesis, warranting further investigation.